Abstract | OBJECTIVE: DATA SOURCES: STUDY SELECTION: Case reports were excluded from this study. DATA EXTRACTION: Of the identified studies, only those published in English describing meta-analyses or randomized controlled trials were considered first. In those aspects with limited or no randomized controlled trials, nonrandomized comparative studies and case series were included also. DATA SYNTHESIS: The prophylactic use of perioperative somatostatin and its analogues to prevent pancreas-related complications after pancreatic surgery remains controversial and does not result in a reduction of operative mortality. There is no clear evidence for or against a particular type of pancreaticoenteric anastomosis. Pancreaticoenterostomy cannot be replaced by pancreatic ductal obliteration. Pancreaticogastrostomy is equivalent to pancreaticojejunostomy in perioperative morbidity and mortality. CONCLUSION: More large-scale comparative studies and randomized controlled trials are required to determine the optimum pharmacologic interventions and technique of pancreaticoenteric anastomosis after pancreatoduodenectomy.
|
Authors | Eric C H Lai, Stephanie H Y Lau, Wan Yee Lau |
Journal | Archives of surgery (Chicago, Ill. : 1960)
(Arch Surg)
Vol. 144
Issue 11
Pg. 1074-80
(Nov 2009)
ISSN: 1538-3644 [Electronic] United States |
PMID | 19917946
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Gastrointestinal Agents
- Octreotide
|
Topics |
- Anastomosis, Surgical
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Male
- Octreotide
(therapeutic use)
- Pancreatic Fistula
(etiology, prevention & control)
- Pancreatic Neoplasms
(surgery)
- Pancreaticoduodenectomy
(adverse effects, methods)
- Pancreaticojejunostomy
(adverse effects, methods)
- Postoperative Complications
(prevention & control)
- Prognosis
- Randomized Controlled Trials as Topic
- Risk Assessment
- Suture Techniques
- Treatment Outcome
|